Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(14):1186-1187; doi:10.1093/jnci/91.14.1186
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ziegler, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ziegler, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 14, 1186-1187, July 21, 1999
© 1999 Oxford University Press

NEWS

Early Trials Probe COX-2 Inhibitors' Cancer-Fighting Potential

Jan Ziegler

Research into COX-2 inhibitors is expanding rapidly out of the animal testing phase, with results so far suggesting that this novel class of compounds may be useful in prevention as well as treatment of colon, skin, and bladder cancer.

The National Cancer Institute is organizing, conducting, or finishing six trials in patients to investigate a variety of endpoints in these three cancers plus Barrett's esophagus, a condition considered a precursor to cancer.

The makers of the two leading COX-2 inhibitor drugs, approved so far only for arthritis and pain relief, said they also would expand . . . [Full Text of this Article]

Before Year's End

One of Six

Other Trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al.
Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda
Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy
Cancer Res., November 15, 2003; 63(22): 7845 - 7852.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne
Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma
Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
J. M. Wallace
Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy
Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37.
[Abstract] [PDF]

Home page
 J. Histochem. Cytochem.Home page
E. M. P. de Almeida, C. Piche, J. Sirois, and M. Dore
Expression of Cyclo-oxygenase-2 in Naturally Occurring Squamous Cell Carcinomas in Dogs
J. Histochem. Cytochem., July 1, 2001; 49(7): 867 - 876.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
F. A. Wollheim
Selective Cox-2 inhibition in man--therapeutic breakthrough or cosmetic advance?
Rheumatology, September 1, 2000; 39(9): 935 - 938.
[Full Text] [PDF]